Tianyin Pharma Approved to Launch Diabetes Treatment

Did you know?

ChinaBio^® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…

More white papers:

>>China Partnering 2012: Driving Future Innovation

>>China Life Science 2012: From Local to Global

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

Tianyin Pharma Approved to Launch Diabetes Treatment

publication date: May 13, 2011

Tianyin Pharma announced SFDA approval for a diabetes drug, Gliclazide Tablets (80 mg formulation). Gliclazide is an oral treatment for type 2 diabetes, administered when diet and exercise are not enough to control blood glucose. Patients take one or two tablets before eating to increase the production of insulin. Tinayin Pharma hopes to launch Gliclazide in July. The company did not issue any revenue projections for its newest product. More details....

Stock Symbol: (AMEX: TPI) Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Click here to join.